Multiple Sclerosis International最新文献

{"title":"Family Planning for People with Multiple Sclerosis in Saudi Arabia: an Expert Consensus.","authors":"Mohammed Al Jumah,&nbsp;Yaser Al Malik,&nbsp;Nuha M AlKhawajah,&nbsp;Jameelah Saeedi,&nbsp;Ibtisam AlThubaiti,&nbsp;Saeed Bohlega,&nbsp;Reem F Bunyan,&nbsp;Edward J Cupler,&nbsp;Ahmed ElBoghdady,&nbsp;Ahmed Hassan,&nbsp;Eman Nassim Ali,&nbsp;Marinella Clerico","doi":"10.1155/2021/6667006","DOIUrl":"https://doi.org/10.1155/2021/6667006","url":null,"abstract":"<p><p>More than half of all patients with multiple sclerosis (MS) in the Kingdom of Saudi Arabia (KSA) are women of childbearing age. Raising a family is an important life goal for women in our region of the world. However, fears and misconceptions about the clinical course of relapsing-remitting MS (RRMS) and the effects of disease-modifying drugs (DMDs) on the foetus have led many women to reduce their expectations of raising a family, sometimes even to the point of avoiding pregnancy altogether. The increase in the number of DMDs available to manage RRMS and recent studies on their effects in pregnancy have broadened management options for these women. Interferon beta now has an indication in Europe for use during pregnancy (according to clinical need) and can be used during breastfeeding. Glatiramer acetate is a further possible option for women with lower levels of RRMS disease activity who are, or about to become, pregnant; natalizumab may be used up to 30 weeks in patients with higher levels of disease activity. Where possible, physicians need to support and encourage women to pursue their dream of a fulfilling family life, supported where necessary by active interventions for RRMS that are increasingly evidence based.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2021 ","pages":"6667006"},"PeriodicalIF":2.5,"publicationDate":"2021-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25408451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Cannabis on the Clinical and Cytokine Profiles in Patients with Multiple Sclerosis.","authors":"Wessam Mustafa,&nbsp;Nadia Elgendy,&nbsp;Samer Salama,&nbsp;Mohamed Jawad,&nbsp;Khaled Eltoukhy","doi":"10.1155/2021/6611897","DOIUrl":"https://doi.org/10.1155/2021/6611897","url":null,"abstract":"<p><strong>Background: </strong>Multiple studies have reported that cannabis administration in multiple sclerosis patients is associated with decreased symptom severity. This study was conducted to evaluate the prevalence of cannabis abuse in multiple sclerosis cases and to evaluate the effect of cannabis on serum cytokines in such cases. <i>Patients and Methods</i>. A total of 150 multiple sclerosis cases along with 150 healthy controls were included during the study period. All cases were subjected to history taking, neurological examination, and routine investigations. Cases were asked about cannabis intake which was confirmed by a urine test. Serum cytokines including IL-1, IL-2, IL-4, IL-10, IL-12, IL-17, IL-22, IFN-<i>γ</i>, IFN-<i>β</i>1, and TNF-<i>α</i> were ordered for all cases and controls.</p><p><strong>Results: </strong>Twenty-eight cases were cannabis abusers (MS/cannabis group, 18.67%). The remaining 122 cases represented the MS group. There was no significant difference between the three groups regarding age, disease duration, or MS type. Male gender was more predominant in the MS/cannabis group, and the number of relapses was significantly lower in the same group. Fifteen cases (53.6%) reported that their symptoms were improved by cannabis. Proinflammatory cytokines were significantly elevated in the MS group compared to the MS/cannabis and control groups. Additionally, anti-inflammatory cytokines had significantly lower values in the MS group compared to the MS/cannabis and control groups. Most clinical symptoms were significantly improved in the MS/cannabis group compared to the MS group apart from sexual dysfunction, bladder symptoms, and visual disturbances. Mild side effects of cannabis were also reported.</p><p><strong>Conclusion: </strong>Cannabis may have a positive impact on the cytokine and clinical profiles in cases with multiple sclerosis.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2021 ","pages":"6611897"},"PeriodicalIF":2.5,"publicationDate":"2021-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884151/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25408450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"miRNA-Dependent CD4⁺ T Cell Differentiation in the Pathogenesis of Multiple Sclerosis.","authors":"Justyna Basak,&nbsp;Ireneusz Majsterek","doi":"10.1155/2021/8825588","DOIUrl":"https://doi.org/10.1155/2021/8825588","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is characterized by multifocal lesions, chronic inflammatory condition, and degenerative processes within the central nervous system (CNS) leading to demyelination. The most important cells involved in its pathogenesis are those which are CD4⁺, particularly proinflammatory Th1/Th17 and regulatory Treg. Signal cascades associated with CD4⁺ differentiation are regulated by microRNAs (miRNAs): short, single-stranded RNAs, responsible for negative regulation of gene expression at the posttranscriptional level. Several miRNAs have been consistently reported as showing dysregulated expression in MS, and their expression patterns may be elevated or decreased, depending on the function of specific miRNA in the immune system. Studies in MS patients indicate that, among others, miR-141, miR-200a, miR-155, miR-223, and miR-326 are upregulated, while miR-15b, miR-20b, miR-26a, and miR-30a are downregulated. Dysregulation of these miRNAs may contribute to the imbalance between pro- and anti-inflammatory processes, since their targets are associated with the regulation of Th1/Th17 and Treg cell differentiation. Highly expressed miRNAs can in turn suppress translation of key Th1/Th17 differentiation inhibitors. miRNA dysregulation may result from the impact of various factors at each stage of their biogenesis. Immature miRNA undergoes multistage transcriptional and posttranscriptional modifications; therefore, any protein involved in the processing of miRNAs can potentially lead to disturbances in their expression. Epigenetic modifications that have a direct impact on miRNA gene transcription may also play an important role.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2021 ","pages":"8825588"},"PeriodicalIF":2.5,"publicationDate":"2021-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38874200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis.","authors":"Vanessa F Moreira Ferreira,&nbsp;Danielle Caefer,&nbsp;Natalie Erlich-Malona,&nbsp;Brian C Healy,&nbsp;Tanuja Chitnis,&nbsp;James M Stankiewicz","doi":"10.1155/2020/5471987","DOIUrl":"https://doi.org/10.1155/2020/5471987","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the safety and efficacy profile of teriflunomide in progressive multiple sclerosis.</p><p><strong>Methods: </strong>We conducted a single-center retrospective observational analysis of a progressive multiple sclerosis population, assessing safety and efficacy in patients treated at least one year with teriflunomide or glatiramer acetate. Sustained progression of expanded disability status scale and sustained worsening of timed 25-foot walk were compared using a Cox proportional hazards model.</p><p><strong>Results: </strong>Teriflunomide group (<i>n</i> = 29) mean characteristics: age = 58 years (SD ± 7.6), disease duration = 16.7 years (SD ± 9.5), expanded disability status score = 5.9 (SD ± 1.3), and follow - up = 32.4 months (SD ± 13.6). Glatiramer acetate group (<i>n</i> = 30) mean characteristics: age = 52.4 years (SD ± 11.3), disease duration = 15.1 years (SD ± 10.4), expanded disability status score = 5.7 (SD ± 1.6), and follow - up = 46.9 months (SD ± 43.9). Both treatments were well tolerated without serious side effects. After adjustment for age, sex, and baseline expanded disability status score, sustained expanded disability status score progression did not differ between groups (hazard ratio = 1.17; 95% confidence interval: 0.45, 3.08; <i>p</i> = 0.75). Sustained timed 25-foot walk worsening after adjustment also did not differ (hazard ratio = 0.56; 95% confidence interval: 0.2, 1.53; <i>p</i> = 0.26).</p><p><strong>Conclusion: </strong>In an advanced progressive multiple sclerosis population, no substantial differences in tolerability, safety, sustained EDSS progression, or sustained T25FW worsening over time were observed between glatiramer acetate and teriflunomide-treated groups. The small sample precluded definitive determination.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2020 ","pages":"5471987"},"PeriodicalIF":2.5,"publicationDate":"2020-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7759400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38767734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Backward Walking and Dual-Task Assessment Improve Identification of Gait Impairments and Fall Risk in Individuals with MS.","authors":"Erin M Edwards,&nbsp;Deborah A Kegelmeyer,&nbsp;Anne D Kloos,&nbsp;Manon Nitta,&nbsp;Danya Raza,&nbsp;Deborah S Nichols-Larsen,&nbsp;Nora E Fritz","doi":"10.1155/2020/6707414","DOIUrl":"https://doi.org/10.1155/2020/6707414","url":null,"abstract":"<p><strong>Background: </strong>Individuals with multiple sclerosis (MS) experience deficits in motor and cognitive domains, resulting in impairment in dual-task walking ability. The goal of this study was to compare performance of forward walking and backward walking in single- and dual-task conditions in persons with MS to age- and sex-matched healthy controls. We also examined relationships between forward and backward walking to cognitive function, balance, and retrospective fall reports.</p><p><strong>Methods: </strong>All measures were collected in a single session. A 2 × 2 × 2 mixed model ANOVA was used to compare differences in forward and backward walking in single- and dual-task conditions between MS and healthy controls. Spearman correlations were used to examine relationships between gait and cognitive function, falls, and balance.</p><p><strong>Results: </strong>Eighteen individuals with relapsing-remitting MS and 14 age- and sex-matched healthy controls participated. Backward walking velocity revealed significant differences between groups for both single-task (<i>p</i> = 0.015) and dual-task (<i>p</i> = 0.014) conditions. Persons with MS demonstrated significant differences between single- and dual-task forward and backward walking velocities (<i>p</i> = 0.023; <i>p</i> = 0.004), whereas this difference was only apparent in the backward walking condition for healthy controls (<i>p</i> = 0.004). In persons with MS, there were significant differences in double support time between single- and dual-task conditions in both backward (<i>p</i> < 0.001) and forward (<i>p</i> = 0.001) directions. More falls at six months were significantly associated with shorter backward dual-task stride length (<i>r</i> = -0.490; <i>p</i> = 0.046) and slower velocity (<i>r</i> = -0.483; <i>p</i> = 0.050).</p><p><strong>Conclusion: </strong>Differences in MS and age- and sex-matched healthy controls are more pronounced during backward compared to forward walking under single- and dual-task conditions. Future work with a larger sample size is needed to validate the clinical utility of backward walking and dual-task assessments and mitigate the limited sensitivity of the current dual-task assessments that primarily rely upon forward walking.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2020 ","pages":"6707414"},"PeriodicalIF":2.5,"publicationDate":"2020-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6707414","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38409454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Lower Urinary Tract Dysfunction Impact on Quality of Life in Multiple Sclerosis Patients: Russian Translation and Validation of SF-Qualiveen.","authors":"Ekaterina S Philippova,&nbsp;Igor V Bazhenov,&nbsp;Alexander V Ziryanov,&nbsp;Ekaterina Y Moskvina","doi":"10.1155/2020/4652439","DOIUrl":"https://doi.org/10.1155/2020/4652439","url":null,"abstract":"<p><p>The Short Form Qualiveen (SF-Qualiveen) is an 8-item version of the Qualiveen questionnaire used to evaluate the impact of urinary symptoms on the quality of life in patients with urological dysfunction due to neurological disorders. The questionnaire was never available in the Russian language before. <i>The study is aimed</i> at providing the translation, cultural adaptation, and validation of a Russian version of the SF-Qualiveen for the use in patients with multiple sclerosis (MS). <i>Materials and Methods</i>. The original English language version of the SF-Qualiveen was translated into Russian according to the cultural and linguistic adaptation algorithm. The participants (50 MS patients with neurogenic bladder and 10 relatively healthy volunteers) filled out the finalized Russian version of the SF-Qualiveen and the Neurogenic Bladder Symptom Score (NBSS) twice, 2 weeks apart. The data obtained was used to determine the internal consistency (Cronbach's alpha), external validity (the Spearman correlation), and test-retest reliability (intraclass correlation coefficient (ICC)) of the questionnaire. <i>Results</i>. The mean SF-Qualiveen total score was 2.51 ± 0.79 in patients with a neurogenic bladder and 0.1 ± 0.02 in the control group (<i>p</i> < 0.001). Cronbach's alpha exceeded 0.9 indicating an excellent internal consistency of the questionnaire. The retest did not reveal any significant differences between the findings. The test-retest reliability was good for all items and domains (ICC 0.81-0.89). The total score demonstrated the highest ICC (0.89). The external validity was verified by a strong correlation demonstrated between the SF-Qualiveen and NBSS scores. <i>Conclusions</i>. The Russian SF-Qualiveen questionnaire is a reliable, valid, and consistent tool for the assessment of a urinary disorder impact on the quality of life in patients with MS.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2020 ","pages":"4652439"},"PeriodicalIF":2.5,"publicationDate":"2020-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/4652439","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38256298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Amino Acid and Acylcarnitine Plasma Profiles for Distinguishing Patients with Multiple Sclerosis from Healthy Controls.","authors":"Marat F Kasakin,&nbsp;Artem D Rogachev,&nbsp;Elena V Predtechenskaya,&nbsp;Vladimir J Zaigraev,&nbsp;Vladimir V Koval,&nbsp;Andrey G Pokrovsky","doi":"10.1155/2020/9010937","DOIUrl":"https://doi.org/10.1155/2020/9010937","url":null,"abstract":"<p><p>McDonald criteria and magnetic resonance imaging (MRI) are used for the diagnosis of multiple sclerosis (MS); nevertheless, it takes a considerable amount of time to make a clinical decision. Amino acid and fatty acid metabolic pathways are disturbed in MS, and this information could be useful for diagnosis. The aim of our study was to find changes in amino acid and acylcarnitine plasma profiles for distinguishing patients with multiple sclerosis from healthy controls. We have applied a targeted metabolomics approach based on tandem mass-spectrometric analysis of amino acids and acylcarnitines in dried plasma spots followed by multivariate statistical analysis for discovery of differences between MS (<i>n</i> = 16) and control (<i>n</i> = 12) groups. It was found that partial least square discriminant analysis yielded better group classification as compared to principal component linear discriminant analysis and the random forest algorithm. All the three models detected noticeable changes in the amino acid and acylcarnitine profiles in the MS group relative to the control group. Our results hold promise for further development of the clinical decision support system.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2020 ","pages":"9010937"},"PeriodicalIF":2.5,"publicationDate":"2020-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/9010937","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38220656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Correlation between Using Social Networks and the General Health of Multiple Sclerosis Patients.","authors":"Atefeh Basirat,&nbsp;Hadi Raeisi Shahraki,&nbsp;Hamid Reza Farpour,&nbsp;Leila Habibi","doi":"10.1155/2020/2791317","DOIUrl":"https://doi.org/10.1155/2020/2791317","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) threatens the patients' independency and ability to effectively participate in the society. The aim of this study was to determine the correlation between using social networks on the general health of multiple sclerosis patients.</p><p><strong>Methods: </strong>This study was performed on 80 MS patients referring to Shiraz University of Medical Sciences, Chamran, and Imam Reza Hospital in 2017, whose condition had improved and were treated by a specialist physician. Tools for data collection were general health questionnaire (GHQ-28) and social networks use questionnaires.</p><p><strong>Results: </strong>Amongst the 80 individuals with MS, 65 (81.3%) were female and 15 (18.8%) were male. Our results suggest that patients with higher levels of education had higher levels of health (<i>P</i> = 0.01). Telegram and WhatsApp, respectively, had a positive correlation with general health (<i>P</i> = 0.007, <i>P</i> = 0.007), anxiety (<i>P</i> = 0.003, <i>P</i> = 0.028), and social dysfunction (<i>P</i> = 0.007, <i>P</i> = 0.007). WhatsApp with 33.64% was the most popular application among MS patients. The correlation between general health and duration of using social networks was not statistically significant (<i>r</i> = 0.22, <i>P</i> = 0.06). Also, no significant correlation was found between the duration of using social networks and the general health (<i>P</i> = 0.62).</p><p><strong>Conclusion: </strong>Our findings suggest that social networks, especially Telegram and WhatsApp, had a positive correlation with general health, anxiety, and social dysfunction of patients. Therefore, the use of social networks can be considered as a suitable option in reducing the aforementioned concerns among patients with MS. On the other hand, general health and mood status might as well influence the use of social network in MS patients.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2020 ","pages":"2791317"},"PeriodicalIF":2.5,"publicationDate":"2020-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/2791317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38178374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis.","authors":"K Daniels,&nbsp;P B van der Nat,&nbsp;S T F M Frequin,&nbsp;P J van der Wees,&nbsp;D H Biesma,&nbsp;E L J Hoogervorst,&nbsp;E M W van de Garde","doi":"10.1155/2020/5463451","DOIUrl":"https://doi.org/10.1155/2020/5463451","url":null,"abstract":"<p><strong>Background: </strong>Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.</p><p><strong>Objective: </strong>The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (<i>n</i> = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).</p><p><strong>Results: </strong>Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (<i>Z</i> = -2.81, <i>p</i> ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.</p><p><strong>Conclusion: </strong>Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2020 ","pages":"5463451"},"PeriodicalIF":2.5,"publicationDate":"2020-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/5463451","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38109787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuromyelitis Optica Spectrum Disorder Attack Triggered by Herpes Zoster Infection.","authors":"Emanuela Claudia Turco,&nbsp;Erica Curti,&nbsp;Valentina Maffini,&nbsp;Francesco Pisani,&nbsp;Franco Granella","doi":"10.1155/2020/6151258","DOIUrl":"https://doi.org/10.1155/2020/6151258","url":null,"abstract":"<p><p>Neuromyelitis optica spectrum disorder is a severe autoimmune disease of the central nervous system characterized by recurrent inflammatory events primarily involving the optic nerves and spinal cord. Recently, a triggering role of infectious events in the development of NMOSD has been suggested. Varicella zoster virus is the most common viral infection involved, though the linkage with anti-aquaporin-4 antibodies is so far unknown. We report, to the best of our knowledge, the first pediatric case report about NMOSD relapse triggered by herpes zoster infection. The strict temporal relationship between VZV infection and NMO attacks seems to be more than simply due to chance; however, further reports are needed to be confirmed.</p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2020 ","pages":"6151258"},"PeriodicalIF":2.5,"publicationDate":"2020-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/6151258","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37905278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}